[AsCNP_P22] ポスター22
Schizophrenia 1

[AsCNP-P22-2] Replacement with the optimal antipsychotics for dopamine supersensitivity (ROADS) study: A multicenter, randomized, assessor-blinded, active-control trial of blonanserin in patients with dopamine supersensitivity psychosis

^○Tomihisa NIITSU¹, Tatsuki HATA^{1, 2}, Masahiko NISHIMOTO³, Yutaka HOSODA^{2, 4}, Ryota SEKI^{1, 5}, Atsushi KIMURA¹, Yasunori ODA¹, Yohei KAWASAKI⁶, Tasuku HASHIMOTO^{1, 7}, Masatomo ISHIKAWA¹, Nobuhisa KANAHARA^{1, 8}, Masaomi IYO^{1, 4, 8}, - THE ROADS STUDY GROUP¹ (1. Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan, 2. Fujita Hospital, Sosa, Chiba, Japan, 3. Soshu Hospital, Atsugi, Kanagawa, Japan, 4. Child Psychiatry, Chiba University Hospital, Chiba, Japan, 5. Chiba Hospital, Funabashi, Chiba, Japan, 6. Clinical Research Center, Chiba University Hospital, Chiba, Japan, 7. Sodegaura-Satsukidai Hospital, Sodegaura, Chiba, Japan, 8. Division of Medical Treatment and Rehabilitation, Center for Forensic Mental Health, Chiba University, Chiba, Japan)